Figures

Numbers that matter

Our goal is to research and develop first-in-class breakthrough medicines that change the lives of people for whom there are no satisfactory treatments available. With our innovations, we have already transformed the health of both human and animal patients around the world. It is our aim to continue doing this in the future.

[**More information in our Highlights** 10min](/content/annualreport/2024/files/figures/BOE_Highlights_2024_EN.pdf "More information in our Highlights"/index.html)

Net Sales By Business

Select Year:

• 2022
• 2023
• 2024

Visualization:

• Bar Chart
• Table

FAQs

How did our product portfolio change last year?

In 2024, Boehringer Ingelheim experienced growth in both the Human Pharma and Animal Health sectors, with a currency-adjusted growth rate of 7% in the former. Key product JARDIANCE® grew currency-adjusted by 15%. The company also invested in R&D, technology, and sustainability, with an increase of around 8% in R&D investments compared with the previous year. The pipeline was enriched with eight special designations, including FDA Fast Track and Breakthrough Designations. The company is on track to launch up to 20 new treatments in Human Pharma by 2030, and 20 additional opportunities in Animal Health by 2026.

What are our pivotal areas of development?

Our key therapeutic areas include oncology, respiratory diseases, mental health, cardio-renal- metabolic diseases. In 2024, we received eight external designations for products in our pipeline in these areas. This includes three FDA Fast Track Designations, two FDA Breakthrough Designations and three Pioneer Drug Designations in Japan. We see these recognitions as an endorsement of our work, and as an incentive to continue to face the most demanding challenges in the future.

What are our primary markets?

Boehringer Ingelheim operates in several key markets both geographically and therapeutically. Geographically, North America is one of our largest markets, particularly the United States, which makes a significant contribution to our revenue. Europe is also a vital region, with significant operations in Germany, where the company is headquartered. In Asia, countries like China and Japan are important due to their large populations and growing healthcare needs. Latin America also plays a crucial role, with notable markets in Brazil and Mexico. We also have a presence in the Middle East, Africa, and Australia.

Therapeutically, Boehringer Ingelheim focuses on several areas within human pharmaceuticals. We have a strong presence in cardiovascular, renal, and metabolic diseases, offering treatments for conditions like diabetes, chronic kidney disease, and heart failure, with products such as JARDIANCE®. In oncology, we are developing treatments for various cancers, including rare types like dedifferentiated liposarcoma. Our respiratory disease portfolio includes products like OFEV® for idiopathic pulmonary fibrosis. We also focus on immunology, mental health, and retinal health, addressing diseases affecting the immune system and the retina. In addition to human pharmaceuticals, Boehringer Ingelheim is a global leader in the animal health industry. We work on innovative solutions for the prediction, prevention, and treatment of diseases in animals, reflecting our commitment to improving health for both humans and animals through innovative therapies and solutions.

What was our R&D investment in 2024?

We are continuing to expand and renew our existing product portfolio in order to safeguard the Group’s organic long-term growth. Accordingly, we have consistently increased our research and development (R&D) expenses in recent years. And with a total of approximately EUR 6.2 billion invested in the research and development of new medicinal products, we have again increased this value compared to the previous year. This corresponds to 23.2% of consolidated net sales. Of this, a large part of the R&D expenditure – EUR 5.7 billion – was invested in the Human Pharma business.